{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:41:52Z","timestamp":1784205712063,"version":"3.55.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.beha.2022.101379","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T02:33:43Z","timestamp":1661826823000},"page":"101379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Accelerated and blast phase myeloproliferative neoplasms"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7336","authenticated-orcid":false,"given":"Antoine N.","family":"Saliba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1 Suppl 2","key":"10.1016\/j.beha.2022.101379_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0037-1963(01)90133-7","article-title":"Chronic myeloid disorders: classification and treatment overview","volume":"38","author":"Tefferi","year":"2001","journal-title":"Semin Hematol"},{"issue":"20","key":"10.1016\/j.beha.2022.101379_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2022.101379_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.beha.2022.101379_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.beha.2022.101379_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J"},{"issue":"14","key":"10.1016\/j.beha.2022.101379_bib6","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2022.101379_bib7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3324\/haematol.2013.094284","volume":"99","author":"Lussana","year":"2014","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.beha.2022.101379_bib8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.leukres.2012.08.013","article-title":"Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium","volume":"36","author":"Mascarenhas","year":"2012","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.beha.2022.101379_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hon.2737","article-title":"Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: real-world data","volume":"38","author":"Palandri","year":"2020","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.beha.2022.101379_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.beha.2022.101379_bib11","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.beha.2022.101379_bib12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2022.101379_bib13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2022.101379_bib14","first-page":"1628","article-title":"The natural history and treatment outcome of blast phase BCR-ABL\u2212 myeloproliferative neoplasms. Blood","volume":"112","author":"Tam","year":"2008","journal-title":"J Am Soc Hematol"},{"issue":"5","key":"10.1016\/j.beha.2022.101379_bib15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.leukres.2010.07.031","article-title":"Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases","volume":"35","author":"Noor","year":"2011","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.beha.2022.101379_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.beha.2022.101379_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.16576","article-title":"Myelofibrosis biology and contemporary management","volume":"191","author":"Gangat","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2022.101379_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.beha.2022.101379_bib19","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2022.101379_bib20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3380","article-title":"Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies","volume":"47","author":"Saliba","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.beha.2022.101379_bib21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2022.101379_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Tapper","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.beha.2022.101379_bib23","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2022.101379_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2022.101379_bib25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"p53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2022.101379_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2022.101379_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0165-4608(02)00678-7","article-title":"Karyotypic abnormalities in myelofibrosis following polycythemia vera","volume":"140","author":"Andrieux","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"10.1016\/j.beha.2022.101379_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2022.101379_bib29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2022.101379_bib30","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2022.101379_bib31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.beha.2022.101379_bib32","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2022.101379_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"issue":"5","key":"10.1016\/j.beha.2022.101379_bib34","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.21297","article-title":"Leukemic transformation of polycythemia vera: a single center study of 23 patients","volume":"104","author":"Passamonti","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.beha.2022.101379_bib35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.clml.2020.12.024","article-title":"Clinical significance of bone marrow blast percentage in patients with myelofibrosis and the effect of ruxolitinib therapy","volume":"21","author":"Masarova","year":"2021","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2022.101379_bib36","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.beha.2022.101379_bib37","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.leukres.2007.12.005","article-title":"Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies","volume":"32","author":"Hussein","year":"2008","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.beha.2022.101379_bib38","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2022.101379_bib39","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2019-132014","article-title":"Landscape of TP53 mutations in MPN","volume":"134","author":"Farnoud","year":"2019","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.beha.2022.101379_bib40","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"10.1016\/j.beha.2022.101379_bib41","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post\u2013polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2022.101379_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0095-2","article-title":"Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis","volume":"8","author":"Mudireddy","year":"2018","journal-title":"Blood Cancer J"},{"issue":"15","key":"10.1016\/j.beha.2022.101379_bib43","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2022.101379_bib44","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2022.101379_bib45","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.beha.2022.101379_bib46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2022.101379_bib47","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2022.101379_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am J Hematol"},{"issue":"29","key":"10.1016\/j.beha.2022.101379_bib49","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2022.101379_bib50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clml.2013.01.001","article-title":"Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia","volume":"13","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"17","key":"10.1016\/j.beha.2022.101379_bib51","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2022.101379_bib52","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/bjh.17423","article-title":"Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era","volume":"193","author":"Shah","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2022.101379_bib53","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","article-title":"Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.beha.2022.101379_bib54","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood.V128.22.1940.1940","article-title":"Survival outcome of patients with acute myeloid leukemia transformed from myeloproliferative neoplasms","volume":"128","author":"Chihara","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2022.101379_bib55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bbmt.2013.10.027","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the myeloproliferative neoplasm subcommittee of the CMWP of the European group for blood and marrow transplantation","volume":"20","author":"Alchalby","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2022.101379_bib56","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2009.12.004","article-title":"Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation","volume":"16","author":"Ciurea","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.beha.2022.101379_bib57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","article-title":"Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase","volume":"36","author":"Cherington","year":"2012","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.beha.2022.101379_bib58","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bmt.2014.31","article-title":"Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Fran\u00e7aise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"49","author":"Cahu","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.beha.2022.101379_bib59","first-page":"405","article-title":"Management of advanced phase myeloproliferative neoplasms","volume":"17","author":"Marcellino","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.beha.2022.101379_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2018.05.004","article-title":"Outcomes and predictors of survival in blast phase myeloproliferative neoplasms","volume":"70","author":"Lancman","year":"2018","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.beha.2022.101379_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156534","article-title":"Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm-blast phase","volume":"7","author":"Wang","year":"2022","journal-title":"JCI Insight"},{"issue":"14","key":"10.1016\/j.beha.2022.101379_bib62","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2022.101379_bib63","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1080\/10428194.2018.1441408","article-title":"Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase","volume":"59","author":"Mollard","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"10.1016\/j.beha.2022.101379_bib64","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","article-title":"The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes","volume":"2","author":"McNamara","year":"2018","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.beha.2022.101379_bib65","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2022.101379_bib66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clml.2014.08.003","article-title":"A phase I\/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"21","key":"10.1016\/j.beha.2022.101379_bib67","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2022.101379_bib68","first-page":"125","article-title":"Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia","volume":"4","author":"Saliba","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"7","key":"10.1016\/j.beha.2022.101379_bib69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101379_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106456","article-title":"Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm","volume":"98","author":"Tremblay","year":"2020","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.beha.2022.101379_bib71","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1111\/bjh.17084","article-title":"Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients","volume":"191","author":"Gangat","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.beha.2022.101379_bib72","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/j.clml.2022.01.015","article-title":"Comparison of different treatment strategies for blast-phase myeloproliferative neoplasms","volume":"22","author":"Castillo Tokumori","year":"2022","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2022.101379_bib73","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/ajh.26381","article-title":"Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms","volume":"97","author":"King","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.beha.2022.101379_bib74","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","article-title":"Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs","volume":"5","author":"Masarova","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.beha.2022.101379_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26334","article-title":"Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia","volume":"96","author":"Saliba","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.beha.2022.101379_bib76","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-021-00555-8","article-title":"6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141\/150)","volume":"11","author":"Wei","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2022.101379_bib77","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.beha.2022.101379_bib78","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.beha.2022.101379_bib79","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.beha.2022.101379_bib80","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2022.101379_bib81","series-title":"Enasidenib vs conventional care in mutant-IDH2 relapsed\/refractory acute myeloidleukemia: a randomized, phase 3 trial","author":"de Botton","year":"2022"},{"issue":"7","key":"10.1016\/j.beha.2022.101379_bib82","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2022.101379_bib83","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2022.101379_bib84","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms","volume":"362","author":"Green","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2022.101379_bib85","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.beha.2022.101379_bib86","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.beha.2022.101379_bib87","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2022.101379_bib88","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2022.101379_bib89","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2022.101379_bib90","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.beha.2022.101379_bib91","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.beha.2022.101379_bib92","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.leukres.2010.05.008","article-title":"Therapeutic options for patients with myelofibrosis in blast phase","volume":"34","author":"Mascarenhas","year":"2010","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.beha.2022.101379_bib93","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.leukres.2015.03.001","article-title":"Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN","volume":"39","author":"Andriani","year":"2015","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.beha.2022.101379_bib94","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"issue":"19","key":"10.1016\/j.beha.2022.101379_bib95","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2022.101379_bib96","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.beha.2022.101379_bib97","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.beha.2022.101379_bib98","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2022.101379_bib99","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2020-138437","volume":"136","author":"Drummond","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2022.101379_bib100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000506146","article-title":"Clinical benefit derived from decitabine therapy for advanced phases of myeloproliferative neoplasms","volume":"144","author":"Zhou","year":"2021","journal-title":"Acta Haematol"},{"issue":"16","key":"10.1016\/j.beha.2022.101379_bib101","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-04-846626","article-title":"A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis","volume":"132","author":"Masarova","year":"2018","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692622000342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:01Z","timestamp":1761498481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692622000342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1521692622000342"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2022.101379","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerated and blast phase myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2022.101379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101379"}}